HER2-Positive Gastric Cancer

被引：0
|
作者：
Haralabos Demetriades
机构：
[1] Aristotle University of Thessaloniki,4th Surgical Department
来源：
Annals of Surgical Oncology | 2011年 / 18卷
关键词：
Gastric Cancer; Trastuzumab; Gastric Cancer Patient; Adjuvant Setting; HER2 Status;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：190 / 191
页数：1
相关论文
共 50 条
  • [31] Current Targeted Therapies in HER2-Positive Gastric Adenocarcinoma
    Curea, Fabiana G.
    Hebbar, Mohamed
    Ilie, Silvia M.
    Bacinschi, Xenia E.
    Trifanescu, Oana G.
    Botnariuc, Inga
    Anghel, Rodica M.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2017, 32 (10) : 351 - 363
  • [32] Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
    Takeru Wakatsuki
    Noriko Yamamoto
    Takeshi Sano
    Keisho Chin
    Hiroshi Kawachi
    Daisuke Takahari
    Mariko Ogura
    Takashi Ichimura
    Izuma Nakayama
    Hiroki Osumi
    Tomohiro Matsushima
    Mitsukuni Suenaga
    Eiji Shinozaki
    Naoki Hiki
    Yuichi Ishikawa
    Kensei Yamaguchi
    Journal of Gastroenterology, 2018, 53 : 1186 - 1195
  • [33] Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
    Wakatsuki, Takeru
    Yamamoto, Noriko
    Sano, Takeshi
    Chin, Keisho
    Kawachi, Hiroshi
    Takahari, Daisuke
    Ogura, Mariko
    Ichimura, Takashi
    Nakayama, Izuma
    Osumi, Hiroki
    Matsushima, Tomohiro
    Suenaga, Mitsukuni
    Shinozaki, Eiji
    Hiki, Naoki
    Ishikawa, Yuichi
    Yamaguchi, Kensei
    JOURNAL OF GASTROENTEROLOGY, 2018, 53 (11) : 1186 - 1195
  • [34] Trastuzumab a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer
    Lordick, Florian
    FUTURE ONCOLOGY, 2011, 7 (02) : 187 - 199
  • [35] A critical review of HER2-positive gastric cancer evaluation and treatment: From trastuzumab, and beyond
    Gomez-Martin, Carlos
    Lopez-Rios, Fernando
    Aparicio, Jorge
    Barriuso, Jorge
    Garcia-Carbonero, Rocio
    Pazo, Roberto
    Rivera, Fernando
    Salgado, Mercedes
    Salud, Antonieta
    Vazquez-Sequeiros, Enrique
    Lordick, Florian
    CANCER LETTERS, 2014, 351 (01) : 30 - 40
  • [36] Irinotecan plus trastuzumab as a second-line treatment for HER2-positive gastric cancer
    Maeda, Osamu
    Ando, Takafumi
    Ishiguro, Kazuhiro
    Watanabe, Osamu
    Miyahara, Ryoji
    Nakamura, Masanao
    Funasaka, Kohei
    Goto, Hidemi
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 224 - 225
  • [37] Chk1 activation attenuates sensitivity of lapatinib in HER2-positive gastric cancer
    Bai, Ming
    Song, Na
    Che, Xiaofang
    Wang, Xiaoxun
    Qu, Xiujuan
    Liu, Yunpeng
    CELL BIOLOGY INTERNATIONAL, 2018, 42 (07) : 781 - 793
  • [38] Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancer
    Fu, Xiaomin
    Zhang, Yong
    Yang, Jing
    Qi, Yalong
    Ming, Yue
    Sun, Miaomiao
    Shang, Yiman
    Yang, Yonghao
    Zhu, Xiaoyan
    Gao, Quanli
    ONCOTARGETS AND THERAPY, 2018, 11 : 6091 - 6100
  • [39] Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab
    Bang, Kyunghye
    Cheon, Jaekyung
    Park, Young Soo
    Kim, Hyung-Don
    Ryu, Min-Hee
    Park, Yangsoon
    Moon, Meesun
    Lee, Hyungeun
    Kang, Yoon-Koo
    GASTRIC CANCER, 2022, 25 (04) : 794 - 803
  • [40] PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer
    Kim, Chan
    Lee, Choong-Kun
    Chon, Hong Jae
    Kim, Joo Hoon
    Park, Hyung Soon
    Heo, Su Jin
    Kim, Hyun Jeong
    Kim, Tae Soo
    Kwon, Woo Sun
    Chung, Hyun Cheol
    Rha, Sun Young
    ONCOTARGET, 2017, 8 (69) : 113494 - 113501
12345